Minerva Neurosciences (NERV) Stock Price, News & Analysis

Company Overview

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Key Stats

• Today's Range: $1.87 to $1.95
• 50-Day Range: $1.46 to $2.17
• 52-Week Range: $1.15 to $3.00
• Volume: 2,623 shs
• Average Volume: 20,799 shs
• Market Capitalization: N/A
• P/E Ratio: 2.35
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

Minerva Neurosciences Stock Analysis - MarketRank™

Minerva Neurosciences scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Minerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Minerva Neurosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Minerva Neurosciences are expected to decrease in the coming year, from ($0.30) to ($2.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Minerva Neurosciences is 2.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Minerva Neurosciences is 2.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.52% of the float of Minerva Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Minerva Neurosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Minerva Neurosciences has recently increased by 3.28%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Minerva Neurosciences does not currently pay a dividend.

Dividend Growth

Minerva Neurosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.89

Percentage of Shares Shorted

0.52% of the float of Minerva Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Minerva Neurosciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Minerva Neurosciences has recently increased by 3.28%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.60% of the stock of Minerva Neurosciences is held by insiders.

Percentage Held by Institutions

Only 34.56% of the stock of Minerva Neurosciences is held by institutions.

NERV Stock Analysis - Frequently Asked Questions

How have NERV shares performed this year?

Minerva Neurosciences' stock was trading at $2.22 at the start of the year. Since then, NERV shares have decreased by 13.3% and is now trading at $1.9250.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc (NASDAQ:NERV) posted its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.57.

When did Minerva Neurosciences' stock split?

Shares of Minerva Neurosciences reverse split on Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/01/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NERV
• CIK: 1598646
• Web: www.minervaneurosciences.com
• Phone: (617) 600-7373
• Fax: N/A
• Employees: 9
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Minerva Neurosciences: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +159.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.82
• Trailing P/E Ratio: 2.35
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $1.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.68%
• Return on Assets: 15.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.21
• Quick Ratio: 9.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.22 per share
• Price / Cash Flow: 8.95
• Book Value: ($3.67) per share
• Price / Book: -0.52

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.32